Sagent issues voluntary recall of injectable anti-inflammatory due to impurities

Sagent issued a voluntary recall of methylprednisolone sodium succinate for injection after finding impurities during routine quality testing. (Pixabay)

Sagent Pharmaceuticals issued a voluntary nationwide recall of 10 lots of methylprednisolone sodium succinate for injection after detecting higher-than-specified impurities during routine quality testing.

The specific impurity has yet to be determined, the company said in a statement, adding that it is not aware of any adverse events to patients who might have used the lots.

The products were manufactured by Gland Pharma Ltd.—which is owned by China's Fosun Pharma—and distributed by Sagent Pharmaceuticals. The impurities were at a level that have the potential to decrease effectiveness of the product in patients.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The lot numbers being recalled were distributed to hospitals, wholesalers and distributors in the U.S. from April 2017 through February 2018.

Methylprednisolone sodium succinate is used as an anti-inflammatory glucocorticoid for the treatment of conditions like allergic reactions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders and other diseases and disorders.

Illinois-based Sagent issued a voluntary recall in 2016 of antibiotics manufactured by one of its India-based contractors after a customer complained that small, dark particulate matter was found in the solution after it was reconstituted. The foreign matter found in the vials was identified as iron oxide.

Suggested Articles

Merck KGaA says it will invest €1 billion in its headquarters site in Darmstadt, Germany, as part of a five-year agreement reached with workers there.

CDMO Thermo Fisher Scientific is investing $150 million to expand biologics and sterile manufacturing at one site in the U.S. and two in Italy.

Mylan is recalling a chemo drug and Hospira a commonly used solution because potentially dangerous particulate has been discovered in vials.